Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SpikoGen as COVID-19 booster in adults
NCT05542862Phase 3Completed
- Sponsor
- Vaxine
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of SpikoGen in coronavirus disease 2019 (COVID-19), sponsored by Vaxine. Primary endpoints: Seroconversion at 4 weeks, Seroprotection at 4 weeks and 8 more. Started Sep 2022; status: completed.
02
Drugs
SpikoGen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05542862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05542862.